Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Salarius Pharmaceuticals ( (SLRX) ) just unveiled an update.
On August 22, 2025, Salarius Pharmaceuticals filed a prospectus supplement for an offering of up to $2.6 million in common stock, as part of an At the Market Offering Agreement with Ladenburg Thalmann & Co. Inc. This move is part of the company’s strategy to raise capital, potentially impacting its financial position and market operations.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. operates within the pharmaceutical industry, focusing on developing innovative therapies for cancer treatment.
Average Trading Volume: 217,854
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.86M
Find detailed analytics on SLRX stock on TipRanks’ Stock Analysis page.